Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With STEMI - BIOSTEMI
Contribution To Literature:
The BIOSTEMI trial showed that biodegradable polymer sirolimus-eluting stents were superior at preventing target lesion failure.
The goal of the trial was to evaluate biodegradable polymer sirolimus-eluting stents compared with durable polymer everolimus-eluting stents among patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
- Bayesian design
Patients with STEMI undergoing primary PCI were randomized to a biodegradable polymer sirolimus-eluting stent (n = 649) vs. a durable polymer everolimus-eluting stent (n = 651).
The biodegradable polymer sirolimus-eluting stent has a strut thickness of 60 μm for stent diameters ≤3.0 mm and 80 μm for stent diameters >3.0 mm (Orsiro; Biotronik). The polymer is biodegradable poly-L-lactic acid that degrades over 12–24 months and releases sirolimus over 12–14 weeks. The durable polymer everolimus-eluting stent has a strut thickness of 81 μm (Xience Xpedition/Alpine; Abbott Vascular). The polymer is poly-n-butyl-methacrylate and vinylidine fluoride and hexafluoropropylene copolymer that releases everolimus.
- Total number of enrollees: 1,300
- Duration of follow-up: 2 years
- Mean patient age: 62 years
- Percentage female: 21%
- Percentage with diabetes: 11%
- Patients ≥18 years of age with STEMI undergoing primary PCI
- Stent thrombosis
- Mechanical complication of MI
The primary outcome, target lesion failure (composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization) at 1 year, occurred in 4% of the biodegradable polymer stents compared with 6% of the durable polymer stents (prespecified criterion for superiority met).
- Cardiac death: 3% with biodegradable polymer stents vs. 6% with durable polymer stents
- Any MI: 2% with biodegradable polymer stents vs. 2% with durable polymer stents
- Definite or probable stent thrombosis: 2% with biodegradable polymer stents vs. 2% with durable polymer stents
Outcomes at 2 years:
- Target lesion failure: 5.1% with biodegradable polymer stents vs. 8.1% with durable polymer stents (Bayesian credible interval 0.40-0.84)
- Clinically indicated target lesion revascularization: 2.5% with biodegradable polymer stents vs. 5.1% with durable polymer stents (Bayesian credible interval 0.30-0.87)
- Definite or probable stent thrombosis: 2.0% with biodegradable polymer stents vs. 2.3% with durable polymer stents
Among patients with STEMI undergoing primary PCI, the ultra-thin biodegradable polymer sirolimus-eluting stent was superior to the durable polymer everolimus-eluting stent. The biodegradable polymer stent design was associated with less target lesion revascularization compared with the durable polymer stent.
The reduction in target lesion failure was sustained at 2 years with the biodegradable polymer sirolimus-eluting stent compared with the durable polymer everolimus-eluting stent. This was due to a significant reduction in the incidence of target lesion revascularization. Definite or probable stent thrombosis was similar between treatment groups.
The comparator stent in this trial has a proven track record, which makes it difficult for any experimental stent to show superiority with outcomes; therefore, these findings are impressive. It is unknown if the latest-generation durable polymer drug-eluting stent (i.e., Xience Sierra) would have resulted in a different outcome.
Pilgrim T, Muller O, Heg D, et al. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial. JACC Cardiovasc Interv 2021;14:639-48.
Editorial Comment: Byrne RA, Coughlan JJ. Biodegradable- Versus Durable-Polymer DES in ST-Segment Elevation Myocardial Infarction: Time to Update Our a Priori Beliefs? JACC Cardiovasc Interv 2021;14:649-52.
Iglesias JF, Muller O, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet 2019;394:1243-53.
Editorial Comment: von Birgelen C, Buiten RA. Superiority of biodegradable polymer sirolimus-eluting stents in STEMI. Lancet 2019;394:1208-10.
Presented by Dr. Juan F. Iglesias at the European Society of Cardiology Congress, Paris, France, September 2, 2019.
Keywords: ESC Congress, ESC 19, Acute Coronary Syndrome, Drug-Eluting Stents, Myocardial Infarction, Myocardial Revascularization, Percutaneous Coronary Intervention, Polymers, Sirolimus, Stents, Thrombosis
< Back to Listings